Eversept Partners LP Has $4.54 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Eversept Partners LP trimmed its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 91.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 343,400 shares of the company's stock after selling 3,761,913 shares during the period. Eversept Partners LP owned 0.40% of Syndax Pharmaceuticals worth $4,540,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stifel Financial Corp acquired a new position in Syndax Pharmaceuticals in the 3rd quarter valued at $327,000. Barclays PLC increased its position in shares of Syndax Pharmaceuticals by 143.4% in the third quarter. Barclays PLC now owns 187,629 shares of the company's stock worth $3,612,000 after purchasing an additional 110,535 shares during the period. Geode Capital Management LLC raised its stake in Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock valued at $38,066,000 after purchasing an additional 66,459 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Syndax Pharmaceuticals during the third quarter worth about $595,000. Finally, Franklin Resources Inc. grew its stake in Syndax Pharmaceuticals by 13.4% during the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock worth $34,948,000 after buying an additional 208,043 shares in the last quarter.

Insider Transactions at Syndax Pharmaceuticals

In related news, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now owns 85,095 shares in the company, valued at $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on SNDX shares. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday, March 20th. StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a research note on Thursday, April 10th. Scotiabank decreased their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Citigroup dropped their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.20.

Syndax Pharmaceuticals Stock Up 0.2 %

Shares of SNDX stock traded up $0.03 during mid-day trading on Friday, reaching $13.33. 756,269 shares of the stock traded hands, compared to its average volume of 1,599,190. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -3.67 and a beta of 1.28. The stock's fifty day simple moving average is $13.08 and its two-hundred day simple moving average is $14.84. Syndax Pharmaceuticals, Inc. has a 1-year low of $9.66 and a 1-year high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. On average, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).